Clinical trials: SARS (Severe Acute Respiratory Syndrome)
Vaccination Hesitancy
Mobile Health-based Motivational Interviewing to Promote COVID-19 Vaccination
The objective of this study is to evaluate the preliminary efficacy and acceptability of an mobile Health-based motivational interviewing (MI) intervention to promote SARS-CoV-2 vaccination (MOTIVACC) compared to traditional…
- Trial name
- COVID-19 (NCT05977192)
- Testing
- Standard MI, Intensive MI, MOTIVACC
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Oklahoma State University
COVID, Covid-19
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
The purpose of this study is to evaluate the safety and effectiveness of APL-9 in adults with mild to moderate ARDS (acute respiratory distress syndrome) caused by COVID-19 who are hospitalized and require supplemental oxygen…
- Conditions
- COVID, Covid-19, Coronavirus, Coronavirus Infection
- Trial name
- NCT04402060
- Testing
- APL-9, Vehicle Control
- Where
- 24 sites in United States, Brazil
- Volunteers
- 72 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Monoclonal B-Cell Lymphocytosis, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies
D1. Primary Objective: 1. Determine the immunogenicity of FDA approved COVID-19 vaccination in patients with hematologic malignancies D2. Secondary Objectives: 1.
- Conditions
- Monoclonal B-Cell Lymphocytosis, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, B-cell Non Hodgkin Lymphoma, Hodgkin Lymphoma
- Trial name
- NCT04748185
- Where
- United States
- Volunteers
- 358 people
- Sponsor
- Mayo Clinic
COVID-19, Coronavirus
A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of pulsed inhaled iNO compared to placebo in subjects with COVID-19.
- Conditions
- COVID-19, Coronavirus, Coronavirus Infection
- Trial name
- COViNOX (NCT04421508)
- Testing
- INOpulse
- Where
- 17 sites in United States
- Volunteers
- 191 people
- Sponsor
- Bellerophon Pulse Technologies
SARS-CoV 2
Association Between BMI and COVID-19
This study will involve collection of pseudonymized data from hospital-based data reporting at multiple international sites. Collating data from a large volume of patients with COVID-19 admitted in ICU across multiple…
- Trial name
- BMI-SARS-CoV-2 (NCT04391738)
- Testing
- Patients admitted to Intensive Care Unit with SARS-CoV2
- Where
- France
- Volunteers
- 1,200 people
- Sponsor
- University Hospital, Lille
Multiple Sclerosis (MS)
Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Vaccination Study
The primary objective of this study is to document immunization status of MS participants after SARS-CoV-2-vaccinations and to evaluate possible effects of disease modifying therapy (DMTs) on the immune status.
- Trial name
- NCT05197699
- Where
- 12 sites in Germany
- Volunteers
- 160 people
- Sponsor
- Biogen
COVID-19, Vaccine Reaction
Evaluation of Inactivated Vaccine in Healthy Adults Against Coronavirus Disease of 2019 (COVID-19)
In this phase 1 study, the inactivated virus vaccine National Research Centre (NRC) Vaccine-101 (VACC-101) will be investigated for its safety and immunogenicity in healthy volunteers with the aim of providing effective and safe…
- Conditions
- COVID-19, Vaccine Reaction, Vaccine Adverse Reaction
- Trial name
- NCT05128721
- Testing
- Covi Vax
- Where
- Egypt
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- National Research Centre, Egypt
SARS-CoV Infection
Remdesivir in COVID-19 Lahore General Hospital
Remdesivir is a monophosphoramidate prodrug of an adenosine analogue and it has a broad-spectrum antiviral activity against paramyxoviruses, falviviruses and coronaviruses.
- Trial name
- RC19LGH (NCT04560231)
- Testing
- Remdesivir
- Where
- Pakistan
- Volunteers
- 30 people
- Sponsor
- Lahore General Hospital
Covid-19
Antioxidant Therapy for COVID-19 Study
Finding effective strategies to treat or prevent the novel coronavirus disease that started in 2019 (COVID-19) is a global public health priority.
- Trial name
- GSHSOD-COVID (NCT04466657)
- Testing
- Antioxidation Therapy, Standard of Care
- Where
- 11 sites in Nigeria
- Sponsor
- Obafemi Awolowo University
SARS-CoV 2
Severe Acute Respiratory Syndrome-Coronavirus-2 and Loss of Autonomy in the Elderly
In most diseases, older people have less typical symptomatology than that described for younger people. The investigators therefore hypothesize that within the framework of coronavirus disease 19, the clinical pictures in the…
- Trial name
- CovAged (NCT04414319)
- Where
- 5 sites in France, Guadeloupe and 1 more
- Volunteers
- 170 people
- Sponsor
- University Hospital Center of Martinique
Rheumatic Diseases, SARS-CoV Infection
Longitudinal Follow-up of Patients With Chronic Inflammatory Rheumatisms (CIRs) Vaccinated Against COVID-19 Compared to Patients Refusing Vaccination
To date, studies on SARS-CoV2and vaccines have been mostly from the general population not exposed to immunosuppressants. The efficacy and safety of COVID-19 vaccines need to be evaluated in these populations.
- Conditions
- Rheumatic Diseases, SARS-CoV Infection, COVID-19
- Trial name
- COVID-RIC3 (NCT04832022)
- Testing
- Biological samples
- Where
- 13 sites in France
- Volunteers
- 397 people
- Sponsor
- University Hospital, Montpellier
SARS-COV2, Severe Acute Respiratory Syndrome
Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2
The goal of this study is to evaluate if CT (Computerized Tomography) can effectively and accurately predict disease progression in patients with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2).
- Conditions
- SARS-COV2, Severe Acute Respiratory Syndrome, COVID-19
- Trial name
- NCT04320511
- Testing
- CT-V
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Corewell Health East
Coronavirus Infection, COVID
COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss
Prone positioning is an established intervention in mechanically ventilated acute respiratory distress syndrome (ARDS) patients, with demonstrated reductions in mortality.
- Conditions
- Coronavirus Infection, COVID, Severe Acute Respiratory Syndrome, Respiratory Failure
- Trial name
- COVAYDE (NCT04395144)
- Testing
- Awake Prone Positioning, Standard care
- Where
- 5 sites in Canada
- Volunteers
- 13 people
- Sponsor
- Hôpital de Verdun
Covid19, SARS-CoV Infection
The DAWN Antivirals Trial for Ambulatory COVID-19 Patients
This is a prospective, placebo controlled, individually randomized controlled phase III trial in Primary Care, assessing the efficacy of antivirals, i.e. camostat and molnupiravir, in accelerating recovery in Covid-19 patients.
- Trial name
- DAWN (NCT04730206)
- Testing
- Camostat, Molnupiravir
- Where
- Belgium
- Volunteers
- 44 people
- Sponsor
- KU Leuven
Coronavirus Infection, Respiratory Disease
Inhaled Ibuprofen to Treat COVID-19
The study aims to evaluate the reduction in severity and progression of lung injury with inhaled ibuprofen in patients with severe acute respiratory syndrome due to SARS-CoV-2 virus.
- Conditions
- Coronavirus Infection, Respiratory Disease, SARS (Disease)
- Trial name
- CórdobaTrail (NCT04382768)
- Testing
- Inhaled Hypertonic ibuprofen
- Where
- Argentina
- Volunteers
- 40 people
- Sponsor
- Química Luar SRL
COVID-19
Randomized Placebo-controlled Trial of Hydroxychloroquine in Outpatient Cases With Coronavirus Disease 2019 (COVID-19)
In December 2019, a group of patients with pneumonia of unknown cause was identified in Wuhan, in the Hubei province, China. Despite the need of target specific therapeutic options for COVID-19, until now there is no proof of…
- Trial name
- COALITION-V (NCT04466540)
- Testing
- Hydroxychloroquine
- Where
- 69 sites in Brazil
- Volunteers
- 1,372 people
- Sponsor
- Hospital Alemão Oswaldo Cruz
COVID-19
LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
This study looks at the safety and effectiveness of LY3819253 in treating COVID-19 in people who have been hospitalized with the infection.
- Trial name
- NCT05780268
- Testing
- LY3819253, Remdesivir
- Where
- 57 sites in United States, Denmark and 2 more
- Volunteers
- 314 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
Plasma Exchange in Covid-19 Patients With Anti-interferon Autoantibodies
COVID-19 associated mortality remains high despite the advances in therapeutics such as dexamethasone. The severity of COVID-19 results from direct viral cytotoxicity, and the inflammatory response, which is associated with a…
- Trial name
- EPIC (NCT05182515)
- Testing
- Therapeutic plasma exchange
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier St Anne
Pneumonitis, SARS-CoV Infection
GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)
This clinical trial will evaluate the safety, tolerability and efficacy of GLS-1027 in the prevention of severe pneumonitis caused by SARS-CoV-2 infection
- Trial name
- NCT04590547
- Testing
- GLS-1027
- Where
- 17 sites in United States, Bulgaria and 3 more
- Volunteers
- 132 people
- Sponsor
- GeneOne Life Science, Inc.
Sequelae of; Infection, Post Infection Glomerulonephritis
Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2
Post-acute sequelae of SARS-CoV-2 infection can cause multiple system function disorders, and complicated symptoms last for an extended period.
- Conditions
- Sequelae of; Infection, Post Infection Glomerulonephritis, Post-Infectious Peripheral Neuralgia, Post-Infectious Disorder (Disorder)
- Trial name
- sequelae (NCT04846010)
- Testing
- PurWet, FurFat, PurApo
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- All Natural Medicine Clinic, LLC